Blue Cross Blue Shield of Michigan reportedly plans to drop coverage of GLP-1 obesity drugs for certain plans due to concerns ...
Blue Cross Blue Shield of Michigan will drop coverage GLP-1 obesity drugs in fully insured large group commercial plans ...
Morgan Stanley expects the market for GLP-1s to be worth a staggering $105 billion by 2030. Long-term, the opportunity looks ...
Obesity affects more than 100 million American adults and nearly 15 million children, putting them at risk for more serious health problems. For many, successfully losing weight is more complicated ...
SANDERS NOTCHES ANOTHER PHARMA WIN — Senate HELP Chair Bernie Sanders (I-Vt.) scored another win in his latest battle with the drug industry, getting Novo Nordisk’s CEO to agree to testify about his ...
Semaglutide (Ozempic, Wegovy) and other drugs in its class are widely known for their role in managing type 2 diabetes and suppressing appetite. They may also prove helpful one day in curbing certain ...
Taking a cutting-edge weight-loss drug could help extremely obese patients drop enough pounds to be eligible for bariatric surgery, a new study shows. Patients with extreme obesity -- a BMI of 70 ...
Many physicians in obesity medicine have observed a trend among their patients: Those with obesity begin taking a weight loss drug like Wegovy, and their other chronic conditions improve or clear ...
Share on Pinterest Metabolic and bariatric surgery is more effective for long-term weight loss than lifestyle changes and GLP-1 medications like Ozempic, Wegovy, and Zepbound. Nastasic/Getty ...
Last year, Americans spent over $50 billion on weight loss drugs like Ozempic and Wegovy. Their popularity, and their price, are having effects throughout the economy. PBS News Hour special ...
An army doctor saved the life of a 27-year-old critically ill man onboard a Pune-Chandigarh flight … ...